| Assay ID | Title | Year | Journal | Article |
|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1890141 | Inhibition of recombinant CDK8 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9
| Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. |
| AID1388682 | Inhibition of CDK19 (unknown origin) | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
| Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
| AID1613761 | Inhibition of recombinant human GST/His-tagged CDK11 (1 to 502 residues)/cyclinC (1 to 283 residues) catalytic domain expressed in insect cells by Lantha screen eu binding assay | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
| AID1890181 | Selectivity index, ratio of IC50 for recombinant CDK19 (unknown origin) to IC50 for recombinant CDK8 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9
| Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. |
| AID1910406 | Transcriptional activity of AP-1 in R848-stimulated mouse BMDC cells transfected with pAP1-luc assessed as ratio of AP-1 activity at 5 uM treated for 24 hrs followed by R484 stimulation for 4 hrs by luminescence based microplate reader analysis relative t | 2022 | Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
| Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease |
| AID1890142 | Inhibition of recombinant CDK19 (unknown origin) | 2022 | Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9
| Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. |
| AID1910405 | Anti-inflammatory activity against R848-stimulated mouse BMDC cells assessed as upregulation of IL-10 production at 5 uM treated for 24 hrs followed by R484 stimulation for 12 hrs by ELISA method (Rvb = 100 %) | 2022 | Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
| Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease |
| AID1613760 | Inhibition of recombinant full-length human His-tagged CDK8/cyclinC expressed in baculovirus expression system by Lantha screen assay | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. |
| AID1910409 | Inhibition of recombinant full length His tagged human CDK8/Cyclin C expressed in Baculovirus incubated for 60 mins in presence of ATP by ADP-Glo kinase assay | 2022 | Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
| Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease |
| AID1388681 | Inhibition of CDK8 (unknown origin) | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
| Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
| AID1388683 | Inhibition of CDK8/Cyclin-C in R848-stimulated mouse BMDC assessed as upregulation of IL-10 level | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
| Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |